NCT06359379Phase 2Terminated

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Study sponsor: Shuttle Pharmaceuticals, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-12-01Actual

Enrollment · participants30Actual

Source updated2025-12-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-18 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~54 participants (planned)~~

+ After

30 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Aug 2026~~

+ After

1 Dec 2025

Recruitment status changed

− Before

~~Recruiting~~

+ After

Terminated

Check registry source

Study details

Conditions studied

Glioblastoma, IDH-wildtype

Treatments or interventions studied

RopidoxuridineDrugAlso known as 5-iodo-2-pyrimidinone-2'-deoxyribose

Primary outcomes · main study measures

Read the study measures

measure: Number of patients treated with oral ropidoxuridine at dose levels of 960 and 1200 mg once daily, with treatment-related adverse events assessed by CTCAE v5.0.; timeFrame: From the first day of treatment start until 30 days after treatment completion; measure: adiographic response rate, disease control rate, best overall response, and duration of overall response in patients treated with oral ropidoxuridine at 960 and 1200 mg daily doses, assessed using the Response Assessment in Neuro-Oncology criteria.; timeFrame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.; measure: Maximum plasma concentration for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily.; timeFrame: he first 36 days of treatment.; measure: Trough plasma concentration of orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily; timeFrame: The first 36 days of treatment.; measure: Time to maximum plasma concentration for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily.; timeFrame: The first 36 days of treatment.; measure: Area under the curve for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily.; timeFrame: The first 36 days of treatment.; measure: Half-life for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily.; timeFrame: The first 36 days of treatment.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history